Indaptus Therapeutics (INDP) Projected to Release Earnings on Tuesday

Indaptus Therapeutics (NASDAQ:INDP) is anticipated to release its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect the company to post earnings of ($1.46) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ:INDP opened at $3.13 on Tuesday. The stock has a market capitalization of $417.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.96. Indaptus Therapeutics has a 1-year low of $0.92 and a 1-year high of $5.96. The company’s fifty day moving average is $2.80 and its two-hundred day moving average is $2.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the body’s immune system to fight cancer and other serious diseases. The company’s approach is based on using attenuated or inactivated bacterial agents to activate multiple components of the immune response.

Indaptus’ lead product candidate is Decoy20, an investigational, systemically administered bacterial immunotherapy. The treatment is designed to engage innate and adaptive immune pathways and potentially improve the body’s ability to recognize and attack tumor cells.